Ordinary Adjustment | Solactive Global Genomics Immunology and Medical Revolution Index | Effective Date 3rd December 2024
Solactive Global Genomics Immunology and Medical Revolution Index:
In the ordinary adjustment, the following composition will be implemented effective open 3rd December 2024:
CRISPR THERAPEUTICS AG |
VERTEX PHARMACEUTICALS INC |
BRISTOL-MYERS SQUIBB CO |
INTELLIA THERAPEUTICS INC |
ASTRAZENECA PLC |
MERCK & CO. INC. |
ABBVIE INC |
ELI LILLY & CO |
PFIZER INC |
THERMO FISHER SCIENTIFIC INC |
ROCHE HOLDING AG |
NOVARTIS AG |
JOHNSON & JOHNSON |
BIONTECH SE |
GENSCRIPT BIOTECH CORP |
BEAM THERAPEUTICS INC |
10X GENOMICS INC |
SANOFI SA |
LONZA GROUP AG |
TWIST BIOSCIENCE CORP |
LEGEND BIOTECH CORP |
BIOGEN INC |
ILLUMINA INC |
QIAGEN NV |
REGENERON PHARMACEUTICALS |
MODERNA INC |
NOVO NORDISK A/S |
SK BIOPHARMACEUTICALS CO LTD |
BIO-TECHNE CORP |
GILEAD SCIENCES INC |
IOVANCE BIOTHERAPEUTICS INC |
SAMSUNG BIOLOGICS CO LTD |
EXACT SCIENCES CORP |
RECURSION PHARMACEUTICALS INC |
GENMAB A/S |
BRIDGEBIO PHARMA INC |
EXELIXIS INC |
SAREPTA THERAPEUTICS INC |
NATERA INC |
GUARDANT HEALTH INC |
AMGEN INC |
ULTRAGENYX PHARMACEUTICAL INC |
TG THERAPEUTICS INC |
AGILENT TECHNOLOGIES INC |
PTC THERAPEUTICS INC |
JAZZ PHARMACEUTICALS PLC |
INCYTE CORP |
INNOVENT BIOLOGICS INC |
BECTON DICKINSON AND CO |
VERACYTE INC |